Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase III IMforte ...
Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback